A Two-Part Adaptive, Randomized Trial of Ridaforolimus in Combination With Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients.
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Dalotuzumab (Primary) ; Ridaforolimus (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 10 Jun 2017 Biomarkers information updated
- 14 Dec 2013 Results for the 2 additional non-randomised reduced-dose treatment arms presented at the 36th Annual San Antonio Breast Cancer Symposium.
- 05 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History